CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,043,610
- in 4 filings, $16.0M under 10b5-1 plans
Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −1,390 | $78.33 | $109K | 112,977 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −21,825 | $78.86 | $1.7M | 91,152 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −1,485 | $80.25 | $119K | 89,667 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −800 | $81.36 | $65K | 88,867 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −2,366 | $82.84 | $196K | 86,501 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −59,800 | $83.90 | $5.0M | 26,701 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −19,469 | $84.57 | $1.6M | 7,232 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −7,232 | $85.54 | $619K | 0 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −74,367 | 10,399 | ||
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −40,000 | 80,000 | ||
| 2026-03-31 | Soteropoulos Paula Director | Option exercise 10b5-1 | +599 | $8.44 | $5K | 599 |
| 2026-03-31 | Soteropoulos Paula Director | Sale 10b5-1 | −599 | $80.11 | $48K | 0 |
| 2026-03-31 | Soteropoulos Paula Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −599 | 599 | ||
| 2026-03-24 | Soteropoulos Paula Director | Option exercise 10b5-1 | +27,594 | $8.44 | $233K | 27,594 |
| 2026-03-24 | Soteropoulos Paula Director | Sale 10b5-1 | −27,594 | $78.05 | $2.2M | 0 |
| 2026-03-24 | Soteropoulos Paula Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,594 | 1,198 | ||
| 2026-03-16 | Garcia Marino CEO AND PRESIDENT | Option exercise | +59,700 | $6.70 | $400K | 59,700 |
| 2026-03-16 | Garcia Marino CEO AND PRESIDENT | Option exercise | +5,592 | $17.88 | $100K | 65,292 |
| 2026-03-16 | Garcia Marino CEO AND PRESIDENT | Option exercise · Stock Option (Right to Buy) | −59,700 | 41 | ||
| 2026-03-16 | Garcia Marino CEO AND PRESIDENT | Option exercise · Stock Option (Right to Buy) | −5,592 | 269,408 |
Page 7 of 24 · 470 trades